The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Published version of a preprint
Abstract
PURPOSE: The G1-S checkpoint of the cell cycle is frequently dysregulated in breast cancer. Palbociclib (PD0332991) is an oral inhibitor of CDK4/6. Based upon preclinical/phase I activity, we performed a phase II, single-arm trial of palbociclib in advanced breast cancer. EXPERIMENTAL DESIGN: Eligible patients had histologically confirmed, metastatic breast cancer positive for retinoblastoma (Rb) protein and measureable disease. Palbociclib was given at 125 mg orally on days 1 to 21 of a 28-day cycle. Primary objectives were tumor response and tolerability. Secondary objectives included progression-free survival (PFS) and assessment of Rb expression/localization, KI-67, p16 loss, and CCND1 amplification. RESULTS: Thirty-seven patients were enrolled; 84% hormone-receptor (HR)(+)/Her2(-), 5% HR(+)/Her2(+), and 11% HR(-)/Her2(-), with a median of 2 prior cytotoxic regimens. Two patients had partial response (PR) and 5 had stable disease ≥ 6 months for a clinical benefit rate (CBR = PR + 6moSD) of 19% overall, 21% in HR(+), and 29% in HR(+)/Her2(-) who had progressed through ≥2 prior lines of hormonal therapy. Median PFS overall was 3.7 months [95% confidence interval (CI), 1.9-5.1], but significantly longer for those with HR(+) versus HR(-) disease (P = 0.03) and those who had previously progressed through endocrine therapy for advanced disease (P = 0.02). Grade 3/4 toxicities included neutropenia (51%), anemia (5%), and thrombocytopenia (22%). Twenty-four percent had treatment interruption and 51% had dose reduction, all for cytopenias. No biomarker identified a sensitive tumor population. CONCLUSIONS: Single-agent palbociclib is well tolerated and active in patients with endocrine-resistant, HR(+), Rb-positive breast cancer. Cytopenias were uncomplicated and easily managed with dose reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stratification related to degree of prior treatment demonstrated that patients with HR+ tumors who had received more than two lines of anti-estrogen therapy had significantly longer PFS than those who had received fewer therapeutic cycles (5 vs. 2 months); the degree of prior cytotoxic regimen exposure did not affect outcome.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [82]
In the citing paper
“Of the HR+/HER2− group, one patient achieved partial response and five had stable disease for ≥ 6 months, with median PFS of 3.8 and 1.5 months for the HR+/HER2− and HR−/HER2− groups, respectively.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [82]
In the citing paper
“Notably, in this trial 24% of patients had treatment interruption and 51% had dose reduction, all for cytopenias.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [82]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 2×
“Response duration in second line hormone therapy is typically 3 to 4months, as evidenced by the 3.7-month PFS seen with both exemestane and fulvestrant in the phase III EFECT trial (22) and the 2.8 month PFS for the exemestane control arm in BOLERO-2 (23).”
BackgroundInfluentialDowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977 · cited 1×
“Ki-67 staining was dichotomized at the 10% staining level (19).”
BackgroundThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“These include cyclin D1 overexpression or amplification, and loss of inhibitors p27 or p16(1-3).”
BackgroundFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“Palbociclib (PD0332991) is an oral inhibitor of the cyclindependent kinases (CDKs) 4 and 6 (8), preventing cell-cycle progression fromG1–S phase, thereby inhibiting cell proliferation and cellular DNA synthesis (9).”
BackgroundExpression and amplification of cyclin genes in human breast cancer.
Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., DeFazio, A., Watts, C. K. W., Musgrove, E. A., & Sutherland, R. L. (1993) · PubMed · Cited by 667
An International Ki67 Reproducibility Study
Polley, M.-Y. C., Leung, S. C. Y., McShane, L. M., Gao, D., Hugh, J. C., Mastropasqua, M. G., Viale, G., Zabaglo, L. A., Penault-Llorca, F., Bartlett, J. M. S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt306 · Cited by 595 · cited 1×
“Ki-67 was stained with a 1:100 dilution of antibody MIB-1 (DAKO), against the MK167 (FHA domain) interacting nucleolar phosphoprotein (14).”
MethodChia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 513
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Metadata
- Authors
- DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., Lewis, D., Langer, M., Goodman, N., Domchek, S., Gogineni, K., Rosen, M., Fox, K., & O'Dwyer, P.
- Affiliations
- Abramson Cancer Center (US)
- University of Pennsylvania (US)
- Corresponding author
- DeMichele, Angela
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2015-03-01
- Volume
- 21
- Issue
- 5
- Pages
- 995-1001
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2067873262
- Cited by
- 343
- References
- 32
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 12 · 2023: 18 · 2022: 25 · 2021: 30 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 51 · 2016: 35 · 2015: 25
- FWCI
- 29.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA016520)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, CDK4/6 inhibitors, retinoblastoma protein, advanced breast cancer, hormone receptor-positive breast cancer, endocrine therapy resistance, G1/S cell cycle checkpoint, progression-free survival, predictive biomarkers, Ki-67, p16 loss, CCND1 amplification
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Piperazines, Prognosis, Pyridines, Biomarkers, Retinoblastoma Protein, Treatment Outcome, Retreatment, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2258
- The paper
- DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., Lewis, D., Langer, M., Goodman, N., Domchek, S., Gogineni, K., Rosen, M., Fox, K., & O'Dwyer, P. (2015). CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2258
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.